A Study of LAD106 in Healthy Adult Participants
Condition(s) studied
Investigational drug(s) / intervention(s)
LAD106: LAD106 will be administered.
Lebrikizumab: Lebrikizumab will be administered.
Placebo: Placebo matching LAD106 will be administered.
Study summary
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.
Eligibility
Primary outcome measure(s)
- Part A (SAD): Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs — From start of study drug up to follow-up (Day 81)
- Part B (MAD): Number of Participants with TEAEs and Severity of TEAEs — From start of study drug up to follow-up (Day 104)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre for Human Drug Research (CHDR) Phase 1 Unit | Leiden | Netherlands | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07471932 on ClinicalTrials.gov ↗ ← All trials in the Netherlands